Literature DB >> 21412686

Decrease in dipeptidyl peptidase IV activity is linked to the efficacy of differentiating compounds in follicular thyroid carcinoma cell lines.

E Fröhlich1, E Engel, R Wahl.   

Abstract

Metastasized differentiated thyroid carcinoma is treated by surgery followed by radioiodine remnant ablation. The application of differentiating agents is a possibility of increasing the efficacy of radioiodine therapy. We evaluated DPP IV and aminopeptidase N, both linked to malignancy in thyroid carcinoma, and dipeptidyl peptidase II activities in human follicular thyroid carcinoma cell lines upon treatment with retinol, apicidine, and lovastatin as differentiating agents. Decrease of dipeptidyl peptidase IV (DPP IV) activity may play a role in the differentiating action. In the human cancer cell lines FTC 138 and 238, high DPP IV and low aminopeptidase N activities were recorded. Retinol treatment induced increases in thyroid-specific protein expression [thyroglobulin and sodium-iodide symporter (NIS)], increase in iodide uptake, and decrease in thymidine uptake accompanied by decrease in DPP IV activity. Decreases in DPP IV activities were also seen upon apicidine and lovastatin treatment, which also increased differentiation of the transformed thyrocytes. Our results demonstrate a link between decrease in DPP IV activity and increase in iodide uptake upon stimulation with differentiating agents. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412686      PMCID: PMC4352318          DOI: 10.1055/s-0031-1273682

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  10 in total

1.  Dipeptidyl peptidase II is not a marker for progression in melanoma.

Authors:  Eleonore Fröhlich; Elke Maier; Andreas F Mack; Claus Garbe
Journal:  J Dermatol Sci       Date:  2008-09-26       Impact factor: 4.563

2.  Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases.

Authors:  Y Aratake; T Kotani; K Tamura; Y Araki; T Kuribayashi; K Konoe; S Ohtaki
Journal:  Am J Clin Pathol       Date:  1991-09       Impact factor: 2.493

Review 3.  Dipeptidyl peptidase II (DPPII), a review.

Authors:  Marie-Berthe Maes; Simon Scharpé; Ingrid De Meester
Journal:  Clin Chim Acta       Date:  2007-02-01       Impact factor: 3.786

4.  Gene expression in poorly differentiated papillary thyroid carcinomas.

Authors:  Øystein Fluge; Ove Bruland; Lars A Akslen; Johan R Lillehaug; Jan E Varhaug
Journal:  Thyroid       Date:  2006-02       Impact factor: 6.568

Review 5.  Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer.

Authors:  Sabrina M Coelho; Mário Vaisman; Denise P Carvalho
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

6.  Biological significance of aminopeptidase N/CD13 in thyroid carcinomas.

Authors:  Astrid Kehlen; Uwe Lendeckel; Henning Dralle; Jürgen Langner; Cuong Hoang-Vu
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

Review 7.  Retinoids in cancer therapy and chemoprevention: promise meets resistance.

Authors:  Sarah J Freemantle; Michael J Spinella; Ethan Dmitrovsky
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

8.  Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands.

Authors:  M J Wilson; A R Ruhland; B J Quast; P K Reddy; S L Ewing; A A Sinha
Journal:  J Androl       Date:  2000 Mar-Apr

9.  Antitumor effects of arsenic trioxide in transformed human thyroid cells.

Authors:  Eleonore Fröhlich; Barbara Czarnocka; Peter Brossart; Richard Wahl
Journal:  Thyroid       Date:  2008-11       Impact factor: 6.568

10.  Direct effects of protirelin (TRH) on cultured porcine thyrocytes.

Authors:  R Wahl; P Brossart; D Eizenberger; H Schuch; E Kallee
Journal:  J Endocrinol Invest       Date:  1992-05       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.